A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer

We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation. Here, we describe a patient who developed secondary FSGS necessitating discontinuation of treatment at first but who was subsequently rechallenged with anti-VEGF-targeted treatment without recurrence of proteinuria. Lenvatinib was a novel experimental agent at the time the treatment took place; however, its recent licensing for the treatment of thyroid malignancies in the UK makes reporting of these adverse effects all the more important now.

Download Full-text

Medullary Thyroid Cancer

Cancer Control ◽

10.1177/107327489700400103 ◽

1997 ◽

Vol 4 (1) ◽

pp. 25-29

Author(s):

Michael G. Franz

Keyword(s):

Thyroid Cancer ◽

Surgical Treatment ◽

Medullary Thyroid Cancer ◽

Early Stage ◽

Medullary Carcinoma ◽

Early Stage Disease ◽

Medullary Thyroid ◽

Central Lymph Node Dissection ◽

Familial Tumors ◽

Thyroid Malignancies

Background Medullary thyroid cancer, a tumor of the parafollicular C cells, accounts for approximately 10% of all thyroid malignancies. An estimated 75% of cases are sporadic, and the remaining 25% are familial. Methods The author reviews the clinical features and diagnostic tests for this entity, as well as the surgical treatment of recurrent or persistent medullary carcinoma. Results Sporadic medullary thyroid cancer typically presents as an isolated unilateral mass. Familial tumors tend to be multifocal and bilateral. In patients with multiple endocrine neoplasia type 2A, pheochromocytomas and parathyroid hyperplasia also may develop. Care is taken to avoid operating on a patient with occult pheochromocytoma. Total thyroidectomy and central lymph node dissection are the keys for successful surgical treatment. Conclusions Surgery is the cornerstone of treatment for medullary carcinoma of the thyroid. Genetic testing using the ret oncogene allows identification of individuals who are at risk for the disease or those with early-stage disease.

Download Full-text

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report

Head and neck tumors (HNT) ◽

10.17650/2222-1468-2019-9-3-38-48 ◽

2019 ◽

Vol 9 (3) ◽

pp. 38-48

Author(s):

А. М. Mudunov ◽

Yu. V. Alymov ◽

I. S. Romanov ◽

S. О. Podvyaznikov ◽

А. V. Ignatova

Keyword(s):

Clinical Trials ◽

Thyroid Cancer ◽

Tyrosine Kinases ◽

Medullary Thyroid Cancer ◽

Locally Advanced ◽

Distant Metastases ◽

Individual Characteristics ◽

Medullary Thyroid ◽

Mechanisms Of Carcinogenesis ◽

Thyroid Malignancies

Medullary thyroid cancer (MTC) is a rare disorder that accounts for approximately 1.7 % of all thyroid malignancies. MTC is usually detected at early stages; however, approximately 10–15 % of patients are diagnosed with locally advanced MTC and distant metastases. Treatment of such patients is challenging due to biological characteristics of the disease and very few effective treatment approaches available. The investigation of mechanisms of carcinogenesis, as well as advances in pharmacology, allowed the development of a new group of targeted drugs, namely tyrosine kinases, which efficacy against progressive unresectable locally advanced or metastatic MTC has been demonstrated in multiple clinical trials. Vandetanib has been registered for MTC treatment in the Russian Federation. MTC is very rare, thus, each case of vandetanib use for its treatment is particularly interesting. Moreover, since the approval of this drug in 2011 by the U. S. Food and Drug Administration (FDA), new data on the clinical use of vandetanib have been accumulated. Importantly, clinical trials are usually well designed and conducted in near-ideal conditions, whereas the real conditions can be different and patients may have individual characteristics. Therefore, the aim of this study was to update the information on the efficacy and safety of vandetanib by retrospective analysis of available publications and to report a case of MTC treated with vandetanib.

Download Full-text

Abstract #1101 The Value of Calcitonin Calcium Stimulation Test Levels as Predictors of Medullary Thyroid Cancer.

Endocrine Practice ◽

10.1016/s1530-891x(20)47466-x ◽

2018 ◽

Vol 24 ◽

pp. 273-274

Author(s):

Corin Badiu ◽

Mara Baet ◽

Ruxandra Dobrescu ◽

Andra Caragheorgheopol ◽

Corneci Cristina

Keyword(s):

Thyroid Cancer ◽

Medullary Thyroid Cancer ◽

Stimulation Test ◽

Medullary Thyroid ◽

Calcium Stimulation

Download Full-text

Intraoperative and postoperative care of unsuspected pheochromocytoma in medullary thyroid cancer

Otolaryngology ◽

10.1016/s0194-5998(94)70538-0 ◽

1994 ◽

Vol 111 (5) ◽

pp. 665-668

Author(s):

S YEE ◽

S STERN

Keyword(s):

Thyroid Cancer ◽

Postoperative Care ◽

Medullary Thyroid Cancer ◽

Medullary Thyroid

Download Full-text

Immunoscintigraphy in Medullary Thyroid Cancer Using an 123I- or 111ln-Labelled Monoclonal Anti-CEA Antibody Fragment

Nuklearmedizin ◽

10.1055/s-0038-1624348 ◽

1986 ◽

Vol 25 (06) ◽

pp. 227-231 ◽

Cited By ~ 6

Author(s):

Chr. Eilles ◽

W. Spiegel ◽

W. Becker ◽

W. Börner ◽

Chr. Reiners

Keyword(s):

Bone Marrow ◽

Thyroid Cancer ◽

Potassium Iodide ◽

Medullary Thyroid Cancer ◽

Elevated Serum ◽

Antibody Fragment ◽

Special Importance ◽

Medullary Thyroid ◽

Medullary Cancer ◽

Serum Cea

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

Download Full-text